Please provide your email address to receive an email when new articles are posted on . Societies issued new guidelines for the screening and treatment of stroke. The new document provides ...

In-hospital ischemic stroke poses unique challenges distinct from community-onset events. Patients already admitted for other conditions often have multiple comorbidities, sedative agents or ...

In January 2026, the American Heart and American Stroke Association (AHA/ASA) issued new care guidelines for acute ischemic stroke (AIS) patients. The entities' "2026 Guideline for the Early ...

The new guideline endorses the use of either alteplase or tenecteplase in the 4.5-hour thrombolytic treatment window. HealthDay News — In a guideline issued by the American Heart Association/American ...

In this forward-looking finale, the panel discusses the transformative shifts expected in stroke management over the next five years. While the introduction of Factor XIa inhibitors like asundexian ...

HELSINKI, Finland — An artificial intelligence (AI)–based clinical decision support system helped doctors make decisions in the treatment of acute ischemic stroke and was associated with a significant ...

Patients with noncardioembolic ischemic stroke or transient ischemic attack (TIA) are at risk for recurrent stroke. Low factor XI levels are associated with a reduced risk of ischemic stroke.

Inclusion in new Acute Ischemic Stroke guidelines underscores clinical utility of Phagenyx for accelerating recovery from swallowing difficulties (dysphagia) in stroke patients NASHVILLE, Tenn., Jan.

A new systematic review and meta-analysis published in the Journal of Periodontology revealed severe periodontitis to be ...

OCEANIC-STROKE shows asundexian cuts ischemic stroke recurrence by 26% in patients taking standard antiplatelet therapy, with no major bleeding increase. Asundexian is a direct oral inhibitor of FXIa ...